The 31 references in paper S. Avdeev N., N. Tsareva A., G. Nekludova V., С. Авдеев Н., Н. Царева А., Г. Неклюдова В. (2014) “Комбинированная терапия ингаляционным илопростом и бозентаном у больной идиопатической легочной гипертензией // Therapy of idiopathic pulmonary hypertension with combination of inhaled iloprost and bosentan” / spz:neicon:pulmonology:y:2013:i:6:p:112-116

1
GaliéN., Hoeper M., Humbert M. et al.Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur. Heart. J.
(check this in PDF content)
2
09; 30: 2493–2537. 2.GaliéN., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 2009; 34: 1219–1263.
(check this in PDF content)
3
McLaughlin V.V., Archer S.L., Badesch D.B. et al.ACCF / AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119: 2250–2294.
(check this in PDF content)
4
Humbert M., Sitbon O., Chaouat A. et al. Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. 2006; 173: 1023–1030.
(check this in PDF content)
5
Peacock A.J., Murphy N.F., McMurray J.J.V. et al.An epidemiological study of pulmonary arterial hypertension. Eur. Respir. J. 2007; 30: 104–109.
(check this in PDF content)
6
Badesch B.D., Champion H.C., Gomez7Sanchez M.A. et al. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2009; 54: S55–S56.
(check this in PDF content)
7
Humbert M., Sitbon O., Chaouat A. et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156–163.
(check this in PDF content)
8
Thenappan T., Shah S.J., Rich S. et al.Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur. Respir. J. 2010; 35: 1079–1087.
(check this in PDF content)
9
Tyndall A.J., Bannert B., Vonk M. et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann. Rheum. Dis. 2010; 69: 1809–1815.
(check this in PDF content)
10
Barst R.J., Rubin L.J., Long W.A. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 1996; 334: 296–302.
(check this in PDF content)
11
McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477–1482.
(check this in PDF content)
12
McLaughlin V.V. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur. J. Clin. Invest. 2006; 36 (Suppl. 13): 10–15.
(check this in PDF content)
13
Sitbon O., McLaughlin V.V., Badesch D.B. et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005; 60: 1025–1030.
(check this in PDF content)
14
Channick R.N., Simonneau G., Sitbon O. et al.Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119–1123.
(check this in PDF content)
15
Rubin L.J., Badesch D.B., Barst R.J. et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2002; 346: 896–903.
(check this in PDF content)
16
Barst R.J., Langleben D., Frost A. et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2004; 169: 441–447.
(check this in PDF content)
17
Barst R.J., Langleben D., Badesch D. et al.Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J. Am. Coll. Cardiol. 2006; 47: 2049–2056.
(check this in PDF content)
18
GaliéN., Ghofrani H.A., Torbicki A. et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2005; 353: 2148–2157.
(check this in PDF content)
19
GaliéN., Olschewski H., Oudiz R.J. et al.Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010–3019.
(check this in PDF content)
20
GaliéN, Brundage BH, Ghofrani HA, et al.Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894–2903.
(check this in PDF content)
21
GaliéN., Rubin L.J., Hoeper M.M. et al.Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093–2100.
(check this in PDF content)
22
Авдеев С.Н., Царева Н.А., Неклюдова Г.В., Чучалин А.Г. Первый клинический опыт применения антагониста рецепторов эндотелина бозентана у пациентов с легочной Авдеев С.Н. и др.Комбинированная терапия ингаляционным илопростом и бозентаном у больной ИЛАГ артериальной гипертензией: результаты 1-годичного исследования. Тер. арх. 2013; 3: 38–43.
(check this in PDF content)
23
GaliéN., Torbicki A., Barst R. et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur. Heart J. 2004; 25: 2243–2278.
(check this in PDF content)
24
Badesch D.B., Abman S.H., Ahearn G.S. et al. Medical therapy for pulmonary arterial hypertension: ACCP evidencebased clinical practice guidelines. Chest 2004; 126 (Suppl. 1): 35S–62S.
(check this in PDF content)
25
Badesch D.B., Abman S.H., Simonneau G. et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131: 1917–1928.
(check this in PDF content)
26
Frishman W.H., Landau A., Cretkovic A. Combination drug therapy with calcium-channel blockers in the treatment of systemic hypertension. J. Clin. Pharmacol. 1993; 33: 752–755.
(check this in PDF content)
27
Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999; 341: 709–717.
(check this in PDF content)
28
Humbert M., Barst R.J., Robbins I.M. et al.Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur. Respir. J. 2004; 24: 353–359.
(check this in PDF content)
29
Hoeper M.M., Leuchte H., Halank M. et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2006; 28: 691–694.
(check this in PDF content)
30
Simonneau G., Rubin L.J., GalièN. et al.Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann. Intern. Med. 2008; 149: 521–530.
(check this in PDF content)
31
McLaughlin V.V., Oudiz R.J., Frost A. et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2006; 174: 1257–1263. Информация об авторах
(check this in PDF content)